Actavis, Aurobindo deal

Aurobindo will acquire Actavis' generics commercial operations in seven Western European markets in a deal valued at about €30 million ($40.7 million). The companies said closing of the deal is conditional on antitrust approvals and completion of employee consultation processes. Specifically, Aurobindo will acquire Actavis' pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands; and enter into a long-term supply arrangement with Actavis. Aurobindo said the deal provides an infrastructure for the company to launch its own injectable and specialty portfolio, and Actavis said the deal will allow it to focus on growth in other markets, including Central and Eastern Europe and Southeast Asia. The companies could not be reached for details. ...